Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Pliability × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neurologic Manifestations 1 Brain Neoplasms 1

Interventions

Docetaxel 257 Prednisone 199 enzalutamide 164 Leuprolide 159 Radiotherapy 151 Abiraterone Acetate 140 Magnetic Resonance Spectroscopy 137 bicalutamide 115 Goserelin 114 Androgen Antagonists 101 Radiosurgery 96 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 95 apalutamide 78 gallium 68 PSMA-11 66 abiraterone 65 Specimen Handling 65 darolutamide 55 Gonadotropin-Releasing Hormone 53 Biopsy 52 Surveys and Questionnaires 51 Radiation 51 Brachytherapy 49 cabazitaxel 46 Triptorelin Pamoate 46 Standard of Care 44 pembrolizumab 43 luprolide acetate gel depot 42 Zoledronic Acid 41 Radiotherapy, Intensity-Modulated 41 Carboplatin 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04485767 2024-08-20

RESIST-ADT (Androgen Deprivation Therapy)

Dana-Farber Cancer Institute

Phase NA Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡